ciprofloxacin has been researched along with Chancroid in 17 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Chancroid: Acute, localized autoinoculable infectious disease usually acquired through sexual contact. Caused by HAEMOPHILUS DUCREYI, it occurs endemically almost worldwide, especially in tropical and subtropical countries and more commonly in seaports and urban areas than in rural areas.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A randomized, double-blind, placebo-controlled clinical trial was conducted in Nairobi, Kenya, to compare single-dose ciprofloxacin with a 7-day course of erythromycin for the treatment of chancroid." | 9.09 | A randomized, double-blind, placebo-controlled trial of single-dose ciprofloxacin versus erythromycin for the treatment of chancroid in Nairobi, Kenya. ( MacDonald, KS; Maclean, I; Malonza, IM; Moses, S; Ndinya-Achola, JO; Omar, S; Orle, K; Perriens, J; Plummer, FA; Ronald, AR; Tyndall, MW, 1999) |
| "Ciprofloxacin and erythromycin are equally effective in chancroid." | 9.08 | A comparative study of therapeutic response of patients with clinical chancroid to ciprofloxacin, erythromycin, and cotrimoxazole. ( D'Souza, P; Khanna, N; Misra, RS; Pandhi, RK; Rattan, A, 1998) |
| "In Kenya, researchers enrolled 53, men aged 18-60 years with chancroid who enrolled at the Nairobi City Council Special Treatment Clinic in a clinical trial to test the efficacy of fleroxacin in clinical Haemophilus ducreyi infections." | 9.06 | Evaluation of fleroxacin (RO 23-6240) as single-oral-dose therapy of culture-proven chancroid in Nairobi, Kenya. ( Cameron, DW; D'Costa, L; MacDonald, KS; Ndinya-Achola, JO; Plummer, FA; Ronald, AR, 1989) |
| "A single dose therapy of 500 mg ciprofloxacin was sufficient to cure 15 of 18 chancroid patients within six days and the remaining three within 7, 11 and 20 days respectively." | 9.06 | Efficacy and safety of a single dose therapy of a 500 mg ciprofloxacin tablet in chancroid patients. ( Tesavibul, P; Traisupa, A; Wongba, C, 1988) |
| "A randomized, double-blind study was performed comparing ciprofloxacin in a 500-mg single dose with 1,000 mg (500-mg doses given 12 h apart) for the treatment of chancroid in Thailand." | 9.06 | Evaluation of 500- and 1,000-mg doses of ciprofloxacin for the treatment of chancroid. ( Bodhidatta, L; Chitwarakorn, A; Echeverria, P; Kuvanont, K; Taylor, DN, 1988) |
| "Ciprofloxacin is a new quinolone antimicrobial agent with excellent in vitro efficacy against H." | 6.66 | Treatment of chancroid with ciprofloxacin. A prospective, randomized clinical trial. ( D'Costa, LJ; Greenblatt, RM; Naamara, W; Ndinya-Achola, JO; Plummer, FA; Ronald, AR, 1987) |
| "A randomized, double-blind, placebo-controlled clinical trial was conducted in Nairobi, Kenya, to compare single-dose ciprofloxacin with a 7-day course of erythromycin for the treatment of chancroid." | 5.09 | A randomized, double-blind, placebo-controlled trial of single-dose ciprofloxacin versus erythromycin for the treatment of chancroid in Nairobi, Kenya. ( MacDonald, KS; Maclean, I; Malonza, IM; Moses, S; Ndinya-Achola, JO; Omar, S; Orle, K; Perriens, J; Plummer, FA; Ronald, AR; Tyndall, MW, 1999) |
| "A comparative open study was performed to evaluate the efficacy of single doses of ciprofloxacin (500 mg) and trimethoprim-sulfamethoxazole (TMP-SMZ; 640 mg/3,200 mg) for the treatment of culture-proven chancroid." | 5.08 | Failure of treatment for chancroid in Rwanda is not related to human immunodeficiency virus infection: in vitro resistance of Haemophilus ducreyi to trimethoprim-sulfamethoxazole. ( Akingeneye, J; Bogaerts, J; Kestens, L; Martinez Tello, W; Mukantabana, V; Piot, P; Van Dyck, E; Verhaegen, J, 1995) |
| "Ciprofloxacin and erythromycin are equally effective in chancroid." | 5.08 | A comparative study of therapeutic response of patients with clinical chancroid to ciprofloxacin, erythromycin, and cotrimoxazole. ( D'Souza, P; Khanna, N; Misra, RS; Pandhi, RK; Rattan, A, 1998) |
| "In Kenya, researchers enrolled 53, men aged 18-60 years with chancroid who enrolled at the Nairobi City Council Special Treatment Clinic in a clinical trial to test the efficacy of fleroxacin in clinical Haemophilus ducreyi infections." | 5.06 | Evaluation of fleroxacin (RO 23-6240) as single-oral-dose therapy of culture-proven chancroid in Nairobi, Kenya. ( Cameron, DW; D'Costa, L; MacDonald, KS; Ndinya-Achola, JO; Plummer, FA; Ronald, AR, 1989) |
| " Treatment failure rates for culture-proven chancroid were 19% for trimethoprim-sulfamethoxazole, 12." | 3.69 | Sexually transmitted diseases and human immunodeficiency virus control in Malawi: a field study of genital ulcer disease. ( Behets, FM; Cohen, MS; Dallabetta, G; Hamilton, HA; Hoffman, IF; Liomba, G; Lule, G; Moeng, S, 1995) |
| "Ciprofloxacin is a new quinolone antimicrobial agent with excellent in vitro efficacy against H." | 2.66 | Treatment of chancroid with ciprofloxacin. A prospective, randomized clinical trial. ( D'Costa, LJ; Greenblatt, RM; Naamara, W; Ndinya-Achola, JO; Plummer, FA; Ronald, AR, 1987) |
| "Treatment with ciprofloxacin for the diagnosis of H." | 1.48 | Haemophilus ducreyi cutaneous ulcer contracted at Seram Island, Indonesia, presented in the Netherlands. ( Bruisten, SM; de Bree, GJ; de Vries, HJC; Grobusch, MP; Kolader, M; Langeveld, TJC; van Hattem, JM, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (23.53) | 18.7374 |
| 1990's | 10 (58.82) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 2 (11.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| van Hattem, JM | 1 |
| Langeveld, TJC | 1 |
| Bruisten, SM | 1 |
| Kolader, M | 1 |
| Grobusch, MP | 1 |
| de Vries, HJC | 1 |
| de Bree, GJ | 1 |
| Trombley, MP | 1 |
| Post, DM | 1 |
| Rinker, SD | 1 |
| Reinders, LM | 1 |
| Fortney, KR | 1 |
| Zwickl, BW | 1 |
| Janowicz, DM | 1 |
| Baye, FM | 1 |
| Katz, BP | 1 |
| Spinola, SM | 2 |
| Bauer, ME | 1 |
| Bogaerts, J | 1 |
| Kestens, L | 1 |
| Martinez Tello, W | 1 |
| Akingeneye, J | 1 |
| Mukantabana, V | 1 |
| Verhaegen, J | 1 |
| Van Dyck, E | 1 |
| Piot, P | 1 |
| Behets, FM | 1 |
| Liomba, G | 1 |
| Lule, G | 1 |
| Dallabetta, G | 1 |
| Hoffman, IF | 1 |
| Hamilton, HA | 1 |
| Moeng, S | 1 |
| Cohen, MS | 1 |
| Ismaeel, NA | 1 |
| Abeck, D | 1 |
| Ballard, RC | 1 |
| Thornton, AC | 1 |
| O'Mara, EM | 1 |
| Sorensen, SJ | 1 |
| Hiltke, TJ | 1 |
| Fortney, K | 1 |
| Katz, B | 1 |
| Shoup, RE | 1 |
| Hood, AF | 1 |
| D'Souza, P | 1 |
| Pandhi, RK | 1 |
| Khanna, N | 1 |
| Rattan, A | 1 |
| Misra, RS | 1 |
| Malonza, IM | 1 |
| Tyndall, MW | 1 |
| Ndinya-Achola, JO | 3 |
| Maclean, I | 1 |
| Omar, S | 1 |
| MacDonald, KS | 2 |
| Perriens, J | 1 |
| Orle, K | 1 |
| Plummer, FA | 3 |
| Ronald, AR | 3 |
| Moses, S | 1 |
| Lewis, DA | 1 |
| Oduor, DO | 1 |
| Bwayo, JJ | 1 |
| Bhatt, SM | 1 |
| Kwasa, TO | 1 |
| Maitha, GM | 1 |
| Ombette, JO | 1 |
| Cameron, DW | 1 |
| D'Costa, L | 1 |
| Traisupa, A | 1 |
| Wongba, C | 1 |
| Tesavibul, P | 1 |
| Bodhidatta, L | 1 |
| Taylor, DN | 1 |
| Chitwarakorn, A | 1 |
| Kuvanont, K | 1 |
| Echeverria, P | 1 |
| Naamara, W | 1 |
| Greenblatt, RM | 1 |
| D'Costa, LJ | 1 |
1 review available for ciprofloxacin and Chancroid
| Article | Year |
|---|---|
Chancroid.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ceftriaxone; Cephalosporins; Chancroid; | 1996 |
8 trials available for ciprofloxacin and Chancroid
| Article | Year |
|---|---|
Failure of treatment for chancroid in Rwanda is not related to human immunodeficiency virus infection: in vitro resistance of Haemophilus ducreyi to trimethoprim-sulfamethoxazole.
Topics: Adult; CD4 Lymphocyte Count; Chancroid; Ciprofloxacin; Drug Resistance, Microbial; Female; Follow-Up | 1995 |
Prevention of experimental Haemophilus ducreyi infection: a randomized, controlled clinical trial.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Chancroid; Ciprofloxacin; Double- | 1998 |
A comparative study of therapeutic response of patients with clinical chancroid to ciprofloxacin, erythromycin, and cotrimoxazole.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Urinary; Chancroid; Cipr | 1998 |
A randomized, double-blind, placebo-controlled trial of single-dose ciprofloxacin versus erythromycin for the treatment of chancroid in Nairobi, Kenya.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Chancroid; Ciprofloxacin; Dou | 1999 |
Evaluation of fleroxacin (RO 23-6240) as single-oral-dose therapy of culture-proven chancroid in Nairobi, Kenya.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; | 1989 |
Efficacy and safety of a single dose therapy of a 500 mg ciprofloxacin tablet in chancroid patients.
Topics: Administration, Oral; Adult; Chancroid; Ciprofloxacin; Clinical Trials as Topic; Humans; Male; Thail | 1988 |
Evaluation of 500- and 1,000-mg doses of ciprofloxacin for the treatment of chancroid.
Topics: Adult; Chancroid; Ciprofloxacin; Clinical Trials as Topic; Double-Blind Method; Drug Administration | 1988 |
Treatment of chancroid with ciprofloxacin. A prospective, randomized clinical trial.
Topics: Adolescent; Adult; Chancroid; Ciprofloxacin; Clinical Trials as Topic; Double-Blind Method; Drug Com | 1987 |
8 other studies available for ciprofloxacin and Chancroid
| Article | Year |
|---|---|
Haemophilus ducreyi cutaneous ulcer contracted at Seram Island, Indonesia, presented in the Netherlands.
Topics: Chancroid; Ciprofloxacin; Haemophilus ducreyi; Humans; Indonesia; Male; Netherlands; Skin Ulcer; Tra | 2018 |
Phosphoethanolamine Transferase LptA in Haemophilus ducreyi Modifies Lipid A and Contributes to Human Defensin Resistance In Vitro.
Topics: Administration, Oral; Adult; alpha-Defensins; Anti-Bacterial Agents; Antimicrobial Cationic Peptides | 2015 |
Sexually transmitted diseases and human immunodeficiency virus control in Malawi: a field study of genital ulcer disease.
Topics: Chancroid; Ciprofloxacin; Erythromycin; Genital Diseases, Male; HIV Infections; Humans; Malawi; Male | 1995 |
In vitro susceptibility of Haemophilus ducreyi to several antibiotics.
Topics: Anti-Bacterial Agents; Ceftriaxone; Chancroid; Ciprofloxacin; Erythromycin; Haemophilus ducreyi; Hum | 1993 |
National guideline for the management of chancroid. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases).
Topics: Anti-Bacterial Agents; Azithromycin; Breast Feeding; Ceftriaxone; Chancroid; Ciprofloxacin; Contrain | 1999 |
Update on the experimental human model for chancroid infection.
Topics: Animals; Anti-Infective Agents; CD4 Lymphocyte Count; Chancroid; Ciprofloxacin; Disease Models, Anim | 2000 |
Chancroid and TMP-SMX.
Topics: Anti-Infective Agents; Chancroid; Ciprofloxacin; HIV Infections; Humans; Trimethoprim, Sulfamethoxaz | 1996 |
Multiple sexually acquired diseases occurring concurrently in an HIV positive man: case report, diagnosis and management.
Topics: Adult; Anti-Infective Agents; Chancroid; Ciprofloxacin; Condylomata Acuminata; Gonorrhea; HIV Seropo | 1992 |